welcome to DuchenneXchange- a positively charged Duchenne muscular dystrophy community.
- join today!
- log in
CRD007 for the Treatment of Duchenne Muscular Dystrophy, Becker Muscular Dystrophy and Symptomatic Carriers
study id #: NCT01540604
condition: Duchenne Muscular Dystrophy , Becker Muscular Dystrophy
This is an investigation of the efficacy and safety of CRD007 in Duchenne Muscular Dystrophy (DMD), Becker Muscular Dystrophy (BMD) and symptomatic carriers.
mechanism of action: Non-steroidal agent to decrease inflammation
last updated: November 22, 2018
phase of development: Phase 2
Documented diagnosis of dystrophinopathy
Severe functional impairment
Study of Ataluren (PTC124®) in Nonambulatory Patients With Nonsense-Mutation-Mediated Duchenne/Becker Muscular Dyst...Duchenne/Becker muscular dystrophy (DMD/...
Clinical Intramuscular Gene Transfer of rAAV1.CMV.huFollistatin344 Trial to Patients With Duchenne Muscular Dystroph...The proposed clinical trial is an outgro...
FDA grants RASRx1902 orphan drug status as potential therapy for Duchenne muscular dystrophyThe U.S. Food and Drug Administration ha...
Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, ran...Background: Duchenne muscular dystrophy...
Capricor Therapeutics Announces Positive Results from its Interim Analysis in the HOPE-2 Trial to Treat Patients wit...Capricor Therapeutics, Inc. (NASDAQ: CAP...
Transplantation of Myoblasts to Duchenne Muscular Dystrophy (DMD) PatientsThis Phase I/II of the clinical trial is...
Capricor Therapeutics Expands Exosome Technology for DMDCapricor Therapeutics is expanding the d...
DuchenneXchange Clinical Trial Finder LaunchesThe DuchenneXchange Clinical Trial Finde...